Blog posts

Cholangiocarcinoma – the rare disease that’s on the increase

By Professor Simon Taylor-Robinson, Consultant Hepatologist and Professor of Translational Medicine at Imperial College London

Cholangiocarcinoma is a rare primary malignancy arising from cholangiocytes, the endothelial lining of the biliary ducts, with an incidence 2500 cases of per annum in the UK. The only option for cure is surgical resection, but cholangiocarcinoma usually presents late when it grows sufficiently to block the drainage of bile from the liver, presenting with jaundice. By this point it is often irresectable, and palliative management includes holding open the ducts with stents to prevent blockage, and chemotherapy. One-year survival is only 5%.

The incidence of this insidious disease is increasing, and earlier diagnosis and better treatment are urgently required.

We can, I can, this World Cancer Day

By Caitriona Tyndall, MSc. BSc, Cancer Research UK Imperial Centre, Department of Surgery and Cancer, Imperial College London.

The 4th of February is World Cancer Day. This is a day to remember and celebrate. Sadly cancer affects us all whether it’s personally or through our friends and family or work colleagues. In fact it’s estimated that 1 in 2 of us will be affected by cancer at some point in our lifetime. But in the face of this depressing statistic there is cause to celebrate. We can celebrate the people we know who have beaten cancer, celebrate the lives of those we have lost and celebrate the ground-breaking research being done by thousands of people across the UK and the world to help beat cancer sooner.

The IGHI Big Data Analytical Unit 2017 – year in review

By Joshua Symons, BDAU, Centre for Health Policy, Institute of Global Health Innovation 

2017 has been a very busy year for the Big Data and Analytical Unit (BDAU). High level accomplishments in data security and researcher outreach have led the BDAU to become one of the most secure and recognised analytic platforms for healthcare data at Imperial.

In May of 2017, the BDAU Secure Environment (SE) became the first ISO 27001:2013 (figure 1) and NHS IG Toolkit 100% Level 3 (figure 2) certified research environment in Imperial College. Over the course of 2017, the BDAU SE was successful in completing a further 11 internal and external audits.

Ending stigma and HIV transmission

By Dr Julia Makinde is a Research Associate with the International AIDS Vaccine Initiative at Imperial College London

It is estimated that there are 36.7 million people living with HIV globally with 1.8 million new infections in 2016 alone (1). This number represents an 11% drop in the number of new infections from 2010 . Some might consider this an achievement or a testament to the impact of strategic national and global policies aimed at tackling the epidemic. But in reality, these numbers mask the discrepant pace in the effort to tackle transmission and AIDS-related deaths in countries across the globe.

Early Diagnosis of Lung Cancer: a Pathologist’s Perspective

By guest blogger, Dr Yu Zhi Zhang (Dennis), Clinical Research Fellow and Specialist Registrar in Histopathology at the National Heart and Lung Institute (NHLI), Imperial College London; on behalf of the National Centre for Mesothelioma Research (NCMR), National Heart and Lung Institute (NHLI), Imperial College London

The 9th edition of the renowned Osler’s Textbook on the Principles and Practice of Medicine, published in 1921, dedicated only two (out of 1,139) pages to lung cancer, at which point the condition was described as “New Growths in the Lungs”. Almost a hundred years on, the patterns of epidemiology have shifted drastically, and lung cancer now is recognised as a major health problem globally with more than 1.8 million new cases diagnosed every year.

Seek advice from a qualified healthcare professional before taking antibiotics

By Dr Timothy Rawson, Clinical Research Fellow, Esmita Charani, Senior Lead Pharmacist and Dr Enrique Castro Sanchez, Academic Research Nurse all from the Faculty of Medicine, Department of Medicine

Antibiotics are a powerful resource that allows us to safely perform surgery, treat cancer with chemotherapy, and recover from infections that over 100 years ago would have killed even the fittest among us.

We are seeing however, a dramatic increase in infections with bacteria resistant to the killing effects of antibiotics (termed drug-resistant infections). These are antibiotics that until recently used to be effective. These resistant bacteria make many infections more and more difficult to treat – in some cases causing patients to die because we no longer have antibiotics that are able to manage the infection.

Using the evidence-based approach to better antibiotic stewardship

By Chris Bird, MSc Health Policy student at Imperial College and Project Manager in the System Engagement Programme at NICE

This week marks World Antibiotic Awareness Week, the theme of which is to seek advice from a qualified healthcare professional before taking antibiotics.

Antibiotic resistance (AMR) is one of the biggest threats to global health, food security and development in our world today. Antibiotic resistance leads to high medical costs, prolonged hospital stays and increased mortality.

It’s a subject brought home to me as I was lucky enough to study my MSc in the very same historic buildings at St Mary’s Hospital where Alexander Fleming first discovered the miracle of penicillin.

Antibiotic resistance is a true global health issue

By guest blogger, Paul Kiet Tang, Senior Assistant Editor at The Lancet*

Since its discovery and widespread use, antibiotics have been marvelled as a panacea that has revolutionised modern day medicine. Routine surgical procedures, childbirth, and open wounds are no longer associated with high risks of mortality from infections. However, the overuse and misuse of these drugs have led to increased concerns of antibiotic resistance worldwide, with up to 700,000 people dying globally from antibiotic-resistant infections. In the final 2016 report of The Review on Antimicrobial Resistance from the UK Government and the Wellcome Trust, this incidence was projected to increase to 10 million people per year by 2050, costing the global economy up to 100 trillion US dollars and pushing about 28.3 million people into extreme poverty.